Emerging Biologics in Severe Asthma - 10/07/16
, Bart Hilvering, MD a, b, c, Rahul Shrimanker, MRCP a, bRésumé |
Asthma is a heterogeneous disease that can be classified into different clinical endotypes, depending on the type of airway inflammation, clinical severity, and response to treatment. This article focuses on the eosinophilic endotype of asthma, which is defined by the central role that eosinophils play in the pathophysiology of the condition. It is characterized by persistently elevated sputum and/or blood eosinophils and by a significant response to treatments that suppress eosinophilia. Eosinophil activity in the airway may be more important than their numbers and this needs to be investigated. Transcriplomic or Metabolomic signatures may also be useful to identify this endotype.
Le texte complet de cet article est disponible en PDF.Keywords : Severe asthma, Biomarkers, Type-2 cytokines, Anti-IL-5, Anti-IL-13, Anti-IL-4&13
Plan
Vol 36 - N° 3
P. 609-623 - août 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
